Vascular Research Training

描述(由申请人提供)：这是耶鲁大学血管研究博士后T32的第二次竞争性续签申请。到目前为止，在完成培训的研究员中，86%获得了学术教师职位，86%进入了独立的科学职业生涯，这是项目成功的有力指标。继续的目标是为高素质的内科医生(医学博士和医学博士/博士)提供实验室和翻译研究培训。以及血管生物学博士后研究员，为血管生物学和医学相关学科的独立研究人员的职业生涯做准备。受训者的选择将基于对血管生物学的承诺和以前丰富的研究经验或潜力。将鼓励临床和基础科学部门的申请，并在全国范围内竞争每年7个名额。少数族裔申请者将被特别征集。培训将以导师为基础，还包括咨询委员会和授课课程。培训的最低期限为2年，大多数研究员将在该计划中停留3年。心血管医学部和耶鲁大学血管生物学和治疗学跨学科项目将是该项目的基础。这一培训计划的一个关键资产是耶鲁大学在血管生物学方面的跨学科优势。参与学院的院系包括心血管内科、肺部和重症监护医学、免疫生物学、药理学、分子细胞和发育生物学、病理学、遗传学、生物工程、生理学、流行病学和公共卫生以及心胸外科。这证明了耶鲁大学强大的血管生物学实验室的广泛范围以及该项目的机构性质。这些教师是根据导师令人印象深刻的历史、持续的血管研究生产力、强大的校外支持以及在项目内担任导师的承诺来选择的。研究机会的例子包括：(1)白细胞-内皮细胞相互作用的分子决定因素和后果；(2)在动物模型中利用核成像和磁共振成像对血管生成和血管重塑进行分子成像；(3)定位和识别与人类血管疾病(动静脉畸形、冠状动脉疾病)发展有关的基因；(4)血管生物材料工程，以及移植后愈合反应的分子决定因素；以及(5)生成用于临床试验的血管生成基因调节剂。这代表了广泛的与疾病相关的血管研究，以及关键的翻译组成部分。学员的进度将由每位导师、学员的顾问委员会和项目总监进行监控。这是我们的期望，我们将培训未来的国内和国际领先的血管研究。心血管疾病是美国的主要死亡原因，也是世界范围内死亡的主要原因。这一计划将为来自多个学科的个人提供重要的机会，最终领导在降低心血管疾病发生率和改善结果方面具有重大影响的努力。

DESCRIPTION (provided by applicant): This is the second competing renewal application for Yale University's Vascular Research Postdoctoral T32. Of fellows who have completed training to date, 86% have obtained academic faculty positions, and 86% have entered independent scientific careers, strong indicators of program success. The continued goal is to provide laboratory and translational research training for highly qualified physician (M.D. and M.D. /Ph.D.) and Ph.D. postdoctoral fellows in vascular biology, in preparation for careers as independent investigators in blood vessel biology- and medicine-related disciplines. Selection of trainees will be based on a commitment to vascular biology and strong prior research experience or potential of same. Applications will be encouraged from clinical and basic science departments, with a nationwide competition for 7 yearly slots. Minority applicants will be specifically solicited. The training will be mentor-based, also including advisory committees and didactic courses. The minimum duration of training will be 2 years, with the majority of fellows remaining in the program for 3 years. The Cardiovascular Medicine Division and Yale's Interdisciplinary Program in Vascular Biology and Therapeutics will be the foundations for the program. A key asset to this training program is Yale's interdisciplinary strength in vascular biology. Departmental affiliations for participating faculty include Cardiovascular Medicine, Pulmonary and Critical Care Medicine, Immunobiology, Pharmacology, Molecular Cellular and Developmental Biology, Pathology, Genetics, Bioengineering, Physiology, Epidemiology and Public Health, and Cardiothoracic Surgery. This is a testimony to the wide spectrum of strong vascular biology laboratories at Yale and the program's institutional nature. The faculty was chosen based on impressive histories of mentorship, ongoing vascular research productivity, strong extramural support and commitment to serve as mentors within the program. Examples of research opportunities include: (1) molecular determinants and consequences of leukocyte-endothelial cell interactions; (2) molecular imaging of angiogenesis and vascular remodeling utilizing nuclear and MR imaging in animal models; (3) mapping and identification of genes that contribute to the development of vascular disease (arterio-venous malformation, coronary artery disease) in humans; (4) engineering of vascular biomaterials, and molecular determinants of healing responses post-implantation; and (5) generation of angiogenic gene regulators for use in clinical trials. This represents a wide range of disease-related vascular research, with key translational components. Trainee progress will be monitored by each mentor, the trainee's advisory committee and the Program Director. It is the expectation that we will train future national and international leaders in vascular research. Cardiovascular disease is the leading cause of death in the U.S., and a major cause of mortality world-wide. This program will provide important opportunities for individuals from multiple disciplines to eventually lead high impact efforts at reducing the incidence of, and improving outcomes in, cardiovascular disease.